Jason Luke

A medical oncologist, Jason Luke, MD, FACP, cares for patients with melanoma and advanced solid tumors. In the context of a multidisciplinary team of doctors and nurses, Dr. Luke works to bring a personalized approach to each patient through a comprehensive, compassionate and individualized care plan that is at the forefront of medicine.

Dr. Luke's research focuses on translational therapeutic advances for melanoma and early phase drug development, particularly immunotherapy. He serves as the national Study Chair for the only on-going national clinical trial for patients with advanced uveal (ocular) melanoma and is the principal investigator of several clinical trials of immunotherapy and targeted molecular therapies for melanoma and advanced cancer.

Prior to coming to the University of Chicago, Dr. Luke was an Instructor in Medicine at the Dana-Farber Cancer Institute and Harvard Medical School where he treated patients with melanoma and performed early phase clinical trials. Dr. Luke joins other interested investigators at the University of Chicago Medicine in creating a comprehensive research program for melanoma and immunotherapeutics for cancer.

Dr. Luke has received advanced training in oncology drug development as a visiting physician at the National Cancer Institute (NCI) and has served on the melanoma science and education program committees for the American Society of Clinical Oncology (ASCO). Dr. Luke has received several awards for his research, including a Young Investigator Award from the Conquer Cancer Foundation of ASCO, an ASCO Merit Award and the Denise and Michael Kellen - Melanoma Research Alliance Young Investigator Award. His research has been supported by ASCO, the NCI and the National Comprehensive Cancer Network.